Show simple item record

dc.contributor.authorLechertier, T
dc.contributor.authorReynolds, LE
dc.contributor.authorKim, H
dc.contributor.authorPedrosa, AR
dc.contributor.authorGómez-Escudero, J
dc.contributor.authorMuñoz-Félix, JM
dc.contributor.authorBatista, S
dc.contributor.authorDukinfield, M
dc.contributor.authorDemircioglu, F
dc.contributor.authorWong, PP
dc.contributor.authorMatchett, KP
dc.contributor.authorHenderson, NC
dc.contributor.authorD'Amico, G
dc.contributor.authorParsons, M
dc.contributor.authorHarwood, C
dc.contributor.authorMeier, P
dc.contributor.authorHodivala-Dilke, KM
dc.date.accessioned2020-06-17T09:54:51Z
dc.date.issued2020-06-04
dc.identifier.citationNature communications, 2020, 11 (1), pp. 2810 - ?
dc.identifier.issn2041-1723
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3748
dc.identifier.eissn2041-1723
dc.identifier.doi10.1038/s41467-020-16618-6
dc.description.abstractThe overexpression of the protein tyrosine kinase, Focal adhesion kinase (FAK), in endothelial cells has implicated its requirement in angiogenesis and tumour growth, but how pericyte FAK regulates tumour angiogenesis is unknown. We show that pericyte FAK regulates tumour growth and angiogenesis in multiple mouse models of melanoma, lung carcinoma and pancreatic B-cell insulinoma and provide evidence that loss of pericyte FAK enhances Gas6-stimulated phosphorylation of the receptor tyrosine kinase, Axl with an upregulation of Cyr61, driving enhanced tumour growth. We further show that pericyte derived Cyr61 instructs tumour cells to elevate expression of the proangiogenic/protumourigenic transmembrane receptor Tissue Factor. Finally, in human melanoma we show that when 50% or more tumour blood vessels are pericyte-FAK negative, melanoma patients are stratified into those with increased tumour size, enhanced blood vessel density and metastasis. Overall our data uncover a previously unknown mechanism of tumour growth by pericytes that is controlled by pericyte FAK.
dc.formatElectronic
dc.format.extent2810 - ?
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectAorta, Thoracic
dc.subjectPericytes
dc.subjectAnimals
dc.subjectMice, Inbred C57BL
dc.subjectMice, Knockout
dc.subjectHumans
dc.subjectMice
dc.subjectNeoplasms
dc.subjectMelanoma
dc.subjectMelanoma, Experimental
dc.subjectCarcinoma, Lewis Lung
dc.subjectNeovascularization, Pathologic
dc.subjectReceptor Protein-Tyrosine Kinases
dc.subjectIntercellular Signaling Peptides and Proteins
dc.subjectVascular Endothelial Growth Factor A
dc.subjectPlatelet-Derived Growth Factor
dc.subjectProto-Oncogene Proteins c-sis
dc.subjectProto-Oncogene Proteins
dc.subjectLymphokines
dc.subjectCell Adhesion
dc.subjectSignal Transduction
dc.subjectCell Proliferation
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectFemale
dc.subjectMale
dc.subjectFocal Adhesion Kinase 1
dc.subjectCysteine-Rich Protein 61
dc.subjectTumor Microenvironment
dc.subjectPlacenta Growth Factor
dc.titlePericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth.
dc.typeJournal Article
dcterms.dateAccepted2020-05-14
rioxxterms.versionofrecord10.1038/s41467-020-16618-6
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-06-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature communications
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Cell Death and Immunity
pubs.publication-statusPublished
pubs.volume11
pubs.embargo.termsNot known
icr.researchteamCell Death and Immunity
dc.contributor.icrauthorMeier, Pascal


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0